Appili therapeutics reports financial and operational results for second quarter of fiscal year 2025

Overwhelming shareholder support in favour of take-private transaction with aditxt studies presented at idweek 2024™ demonstrate ati-1701 provides full protection against lethal tularemia in animal models after one year alignment with u.s. food and drug administration on development requirements for ati-1801 nda submission halifax, nova scotia, nov. 14, 2024 (globe newswire) -- appili therapeutics inc. (tsx:apli; otcpink: aplif) (the “company” or “appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the second quarter of its fiscal year 2025, which ended on september 30, 2024. all figures are stated in canadian dollars unless otherwise stated.
ATI Ratings Summary
ATI Quant Ranking